MRKR Marker Therapeutics Inc.

-0.2  -4%
Previous Close 4.51
Open 4.49
Price To Book 3.81
Market Cap 196,840,273
Shares 45,670,597
Volume 156,657
Short Ratio
Av. Daily Volume 283,741
Stock charts supplied by TradingView

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 interim data due 4Q 2019.
Platinum-sensitive ovarian cancer
26/27 patients have shown immune response.
Second line triple-negative breast cancer (TNBC)
Phase 1/2 data presented at ASH 2018.
MultiTAA-Specific T Cells
Multiple Myeloma
Phase 1/2 trial ongoing.
MultiTAA-Specific T Cells
Phase 2 trial to be initiated later in 2019.
MultiTAA-Specific T Cells
Acute Myeloid Leukemia
Phase 1/2 data at AACR noted 3/9 patients with objective responses.
MultiTAA-Specific T Cells
Pancreatic cancer